|
1
|
Griffiths-Jones S, Grocock RJ, van Dongen
S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets
and gene nomenclature. Nucleic Acids Res. 34:D140–D144. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim VN: MicroRNA biogenesis: Coordinated
cropping and dicing. Nat Rev Mol Cell Biol. 6:376–385. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feng YH, Wu CL, Tsao CJ, Chang JG, Lu PJ,
Yeh KT, Uen YH, Lee JC and Shiau AL: Deregulated expression of
sprouty2 and microRNA-21 in human colon cancer: Correlation with
the clinical stage of the disease. Cancer Biol Ther. 11:111–121.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fulci V, Chiaretti S, Goldoni M, Azzalin
G, Carucci N, Tavolaro S, Castellano L, Magrelli A, Citarella F,
Messina M, et al: Quantitative technologies establish a novel
microRNA profile of chronic lymphocytic leukemia. Blood.
109:4944–4951. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Medina PP, Nolde M and Slack FJ: OncomiR
addiction in an in vivo model of microRNA-21-induced pre-B-cell
lymphoma. Nature. 467:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sheedy FJ: Turning 21: Induction of miR-21
as a key switch in the inflammatory response. Front Immunol.
6:192015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma X, Conklin DJ, Li F, Dai Z, Hua X, Li
Y, Xu-Monette ZY, Young KH, Xiong W, Wysoczynski M, et al: The
oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nat
Commun. 6:71512015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krichevsky AM and Gabriely G: miR-21: A
small multi-faceted RNA. J Cell Mol Med. 13:39–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Selcuklu SD, Donoghue MT and Spillane C:
miR-21 as a key regulator of oncogenic processes. Biochem Soc
Trans. 37:918–925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roldo C, Missiaglia E, Hagan JP, Falconi
M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, et
al: MicroRNA expression abnormalities in pancreatic endocrine and
acinar tumors are associated with distinctive pathologic features
and clinical behavior. J Clin Oncol. 24:4677–4684. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tatsuguchi M, Seok HY, Callis TE, Thomson
JM, Chen JF, Newman M, Rojas M, Hammond SM and Wang DZ: Expression
of microRNAs is dynamically regulated during cardiomyocyte
hypertrophy. J Mol Cell Cardiol. 42:1137–1141. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen
H, Dean DB and Zhang C: MicroRNA expression signature and
antisense-mediated depletion reveal an essential role of MicroRNA
in vascular neointimal lesion formation. Circ Res. 100:1579–1588.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Landgraf P, Rusu M, Sheridan R, Sewer A,
Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M,
et al: A mammalian microRNA expression atlas based on small RNA
library sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu TX, Munitz A and Rothenberg ME:
MicroRNA-21 is up-regulated in allergic airway inflammation and
regulates IL-12p35 expression. J Immunol. 182:4994–5002. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu TX, Hartner J, Lim EJ, Fabry V, Mingler
MK, Cole ET, Orkin SH, Aronow BJ and Rothenberg ME: MicroRNA-21
limits in vivo immune response-mediated activation of the
IL-12/IFN-gamma pathway, Th1 polarization, and the severity of
delayed-type hypersensitivity. J Immunol. 187:3362–3373. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Murugaiyan G, Garo LP and Weiner HL:
MicroRNA-21, T helper lineage and autoimmunity. Oncotarget.
6:9644–9645. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujita S, Ito T, Mizutani T, Minoguchi S,
Yamamichi N, Sakurai K and Iba H: miR-21 Gene expression triggered
by AP-1 is sustained through a double-negative feedback mechanism.
J Mol Biol. 378:492–504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan X, Wang ZX and Wang R: MicroRNA-21: A
novel therapeutic target in human cancer. Cancer Biol Ther.
10:1224–1232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Löffler D, Brocke-Heidrich K, Pfeifer G,
Stocsits C, Hackermüller J, Kretzschmar AK, Burger R, Gramatzki M,
Blumert C, Bauer K, et al: Interleukin-6 dependent survival of
multiple myeloma cells involves the Stat3-mediated induction of
microRNA-21 through a highly conserved enhancer. Blood.
110:1330–1333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang HS, Knies JL, Stark C and Colburn NH:
Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1
transactivation. Oncogene. 22:3712–3720. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hatley ME, Patrick DM, Garcia MR,
Richardson JA, Bassel-Duby R, van Rooij E and Olson EN: Modulation
of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell.
18:282–293. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21
targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol
Chem. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schramedei K, Mörbt N, Pfeifer G, Läuter
J, Rosolowski M, Tomm JM, von Bergen M, Horn F and Brocke-Heidrich
K: MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4.
Oncogene. 30:2975–2985. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gabriely G, Wurdinger T, Kesari S, Esau
CC, Burchard J, Linsley PS and Krichevsky AM: MicroRNA 21 promotes
glioma invasion by targeting matrix metalloproteinase regulators.
Mol Cell Biol. 28:5369–5380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thorland EC, Myers SL, Gostout BS and
Smith DI: Common fragile sites are preferential targets for HPV16
integrations in cervical tumors. Oncogene. 22:1225–1237. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu H, Ng R, Chen X, Steer CJ and Song G:
MicroRNA-21 is a potential link between non-alcoholic fatty liver
disease and hepatocellular carcinoma via modulation of the
HBP1-p53-Srebp1c pathway. Gut gutjnl-2014-308430. 2015.
|
|
32
|
Gu L, Song G, Chen L, Nie Z, He B, Pan Y,
Xu Y, Li R, Gao T, Cho WC, et al: Inhibition of miR-21 induces
biological and behavioral alterations in diffuse large B-cell
lymphoma. Acta Haematol. 130:87–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Davis RE, Ngo VN, Lenz G, Tolar P, Young
RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al:
Chronic active B-cell-receptor signalling in diffuse large B-cell
lymphoma. Nature. 463:88–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pfeifer M, Grau M, Lenze D, Wenzel SS,
Wolf A, Wollert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, et
al: PTEN loss defines a PI3K/AKT pathway-dependent germinal center
subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA.
110:12420–12425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hong JY, Hong ME, Choi MK, Kim YS, Chang
W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, et al: The impact of
activated p-AKT expression on clinical outcomes in diffuse large
B-cell lymphoma: A clinicopathological study of 262 cases. Ann
Oncol. 25:182–188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Go H, Jang JY, Kim PJ, Kim YG, Nam SJ,
Paik JH, Kim TM, Heo DS, Kim CW and Jeon YK: MicroRNA-21 plays an
oncogenic role by targeting FOXO1 and activating the PI3K/AKT
pathway in diffuse large B-cell lymphoma. Oncotarget.
6:15035–15049. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Karube K, Nakagawa M, Tsuzuki S, Takeuchi
I, Honma K, Nakashima Y, Shimizu N, Ko YH, Morishima Y, Ohshima K,
et al: Identification of FOXO3 and PRDM1 as tumor-suppressor gene
candidates in NK-cell neoplasms by genomic and functional analyses.
Blood. 118:3195–3204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yin Q, McBride J, Fewell C, Lacey M, Wang
X, Lin Z, Cameron J and Flemington EK: MicroRNA-155 is an
Epstein-Barr virus-induced gene that modulates Epstein-Barr
virus-regulated gene expression pathways. J Virol. 82:5295–5306.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen W, Wang H, Chen H, Liu S, Lu H, Kong
D, Huang X, Kong Q and Lu Z: Clinical significance and detection of
microRNA-21 in serum of patients with diffuse large B-cell lymphoma
in Chinese population. Eur J Haematol. 92:407–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jones K, Nourse JP, Keane C, Bhatnagar A
and Gandhi MK: Plasma microRNA are disease response biomarkers in
classical Hodgkin lymphoma. Clin Cancer Res. 20:253–264. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Anger B, Carbonell F, Braunger I, Heinze
B, Gutensohn W, Thiel E and Heimpel H: Blast crisis of Philadelphia
chromosome-positive chronic myelocytic leukemia (CML). Treatment
results of 69 patients. Blut. 57:131–137. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou M, Zeng J, Wang X, Wang X, Huang T,
Fu Y, Sun T, Jia J and Chen C: Histone demethylase RBP2 decreases
miR-21 in blast crisis of chronic myeloid leukemia. Oncotarget.
6:1249–1261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ruiz-Lafuente N, Alcaraz-García MJ,
Sebastián-Ruiz S, García-Serna AM, Gómez-Espuch J, Moraleda JM,
Minguela A, García-Alonso AM and Parrado A: IL-4 up-regulates
MiR-21 and the MiRNAs hosted in the CLCN5 gene in chronic
lymphocytic leukemia. PLoS One. 10:e01249362015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rossi S, Shimizu M, Barbarotto E, Nicoloso
MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti
LZ, et al: microRNA fingerprinting of CLL patients with chromosome
17p deletion identify a miR-21 score that stratifies early
survival. Blood. 116:945–952. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Riccioni R, Lulli V, Castelli G, Biffoni
M, Tiberio R, Pelosi E, Lo-Coco F and Testa U: miR-21 is
overexpressed in NPM1-mutant acute myeloid leukemias. Leuk Res.
39:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Junker F, Chabloz A, Koch U and Radtke F:
Dicer1 imparts essential survival cues in Notch-driven T-ALL via
miR-21-mediated tumor suppressor Pdcd4 repression. Blood.
126:993–1004. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Leone E, Morelli E, Di Martino MT, Amodio
N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, et
al: Targeting miR-21 inhibits in vitro and in vivo multiple myeloma
cell growth. Clin Cancer Res. 19:2096–2106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang JH, Zhou WW, Cheng ST, Liu BX, Liu FR
and Song JQ: Downregulation of Sprouty homolog 2 by microRNA-21
inhibits proliferation, metastasis and invasion, however promotes
the apoptosis of multiple myeloma cells. Mol Med Rep. 12:1810–1816.
2015.PubMed/NCBI
|
|
49
|
Wang W, Li J, Zhu W, Gao C, Jiang R, Li W,
Hu Q and Zhang B: MicroRNA-21 and the clinical outcomes of various
carcinomas: A systematic review and meta-analysis. BMC Cancer.
14:8192014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yan LX, Huang XF, Shao Q, Huang MY, Deng
L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in
human breast cancer is associated with advanced clinical stage,
lymph node metastasis and patient poor prognosis. RNA.
14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang ZJ and Ma SL: miRNAs in breast
cancer tumorigenesis (Review). Oncol Rep. 27:903–910.
2012.PubMed/NCBI
|
|
52
|
Venturutti L, Romero LV, Urtreger AJ,
Chervo MF, Russo RI Cordo, Mercogliano MF, Inurrigarro G, Pereyra
MG, Proietti CJ, Izzo F, et al: Stat3 regulates ErbB-2 expression
and co-opts ErbB-2 nuclear function to induce miR-21 expression,
PDCD4 downregulation and breast cancer metastasis. Oncogene.
35:2208–2222. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Erbes T, Hirschfeld M, Rücker G, Jaeger M,
Boas J, Iborra S, Mayer S, Gitsch G and Stickeler E: Feasibility of
urinary microRNA detection in breast cancer patients and its
potential as an innovative non-invasive biomarker. BMC Cancer.
15:1932015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li S, Yang X, Yang J, Zhen J and Zhang D:
Serum microRNA-21 as a potential diagnostic biomarker for breast
cancer: A systematic review and meta-analysis. Clin Exp Med.
16:29–35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Asangani IA, Rasheed SA, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yu Y, Nangia-Makker P, Farhana LG,
Rajendra S, Levi E and Majumdar AP: miR-21 and miR-145 cooperation
in regulation of colon cancer stem cells. Mol Cancer. 14:982015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Dong Y, Yu J and Ng SS: MicroRNA
dysregulation as a prognostic biomarker in colorectal cancer.
Cancer Manag Res. 6:405–422. 2014.PubMed/NCBI
|
|
58
|
Nielsen BS, Jørgensen S, Fog JU, Søkilde
R, Christensen IJ, Hansen U, Brünner N, Baker A, Møller S and
Nielsen HJ: High levels of microRNA-21 in the stroma of colorectal
cancers predict short disease-free survival in stage II colon
cancer patients. Clin Exp Metastasis. 28:27–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang JX, Song W, Chen ZH, Wei JH, Liao
YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, et al: Prognostic and
predictive value of a microRNA signature in stage II colon cancer:
A microRNA expression analysis. Lancet Oncol. 14:1295–1306. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Seike M, Goto A, Okano T, Bowman ED,
Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, et
al: miR-21 is an EGFR-regulated anti-apoptotic factor in lung
cancer in never-smokers. Proc Natl Acad Sci USA. 106:12085–12090.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ma XL, Liu L, Liu XX, Li Y, Deng L, Xiao
ZL, Liu YT, Shi HS and Wei YQ: Prognostic role of microRNA-21 in
non-small cell lung cancer: A meta-analysis. Asian Pac J Cancer
Prev. 13:2329–2334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F,
Wang X, He X and Zhao Y and Zhao Y: Prognostic role of microRNA-21
in various carcinomas: A systematic review and meta-analysis. Eur J
Clin Invest. 41:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang X, Zhang J, Zhou L, Lu P, Zheng ZG,
Sun W, Wang JL, Yang XS, Li XL, Xia N, et al: Significance of serum
microRNA-21 in diagnosis of hepatocellular carcinoma (HCC):
Clinical analyses of patients and an HCC rat model. Int J Clin Exp
Pathol. 8:1466–1478. 2015.PubMed/NCBI
|
|
64
|
Ribas J, Ni X, Haffner M, Wentzel EA,
Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J,
Rodriguez R, et al: miR-21: An androgen receptor-regulated microRNA
that promotes hormone-dependent and hormone-independent prostate
cancer growth. Cancer Res. 69:7165–7169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Reis ST, Pontes-Junior J, Antunes AA,
Dall'Oglio MF, Dip N, Passerotti CC, Rossini GA, Morais DR,
Nesrallah AJ, Piantino C, et al: miR-21 may acts as an oncomir by
targeting RECK, a matrix metalloproteinase regulator, in prostate
cancer. BMC Urol. 12:142012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Coppola V, Musumeci M, Patrizii M,
Cannistraci A, Addario A, Maugeri-Saccà M, Biffoni M,
Francescangeli F, Cordenonsi M, Piccolo S, et al: BTG2 loss and
miR-21 upregulation contribute to prostate cell transformation by
inducing luminal markers expression and epithelial-mesenchymal
transition. Oncogene. 32:1843–1853. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Li T, Li RS, Li YH, Zhong S, Chen YY,
Zhang CM, Hu MM and Shen ZJ: miR-21 as an independent biochemical
recurrence predictor and potential therapeutic target for prostate
cancer. J Urol. 187:1466–1472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Samsonov R, Shtam T, Burdakov V, Glotov A,
Tsyrlina E, Berstein L, Nosov A, Evtushenko V, Filatov M and Malek
A: Lectin-induced agglutination method of urinary exosomes
isolation followed by mi-RNA analysis: Application for prostate
cancer diagnostic. Prostate. 76:68–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Koppers-Lalic D, Hackenberg M, de Menezes
R, Misovic B, Wachalska M, Geldof A, Zini N, de Reijke T, Wurdinger
T, Vis A, et al: Non-invasive prostate cancer detection by
measuring miRNA variants (isomiRs) in urine extracellular vesicles.
Oncotarget. 7:22566–22578. 2016.PubMed/NCBI
|
|
70
|
Hong L, Han Y, Zhang Y, Zhang H, Zhao Q,
Wu K and Fan D: MicroRNA-21: A therapeutic target for reversing
drug resistance in cancer. Expert Opin Ther Targets. 17:1073–1080.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chen Z, Yuan YC, Wang Y, Liu Z, Chan HJ
and Chen S: Down-regulation of programmed cell death 4 (PDCD4) is
associated with aromatase inhibitor resistance and a poor prognosis
in estrogen receptor-positive breast cancer. Breast Cancer Res
Treat. 152:29–39. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yu X, Li R, Shi W, Jiang T, Wang Y, Li C
and Qu X: Silencing of MicroRNA-21 confers the sensitivity to
tamoxifen and fulvestrant by enhancing autophagic cell death
through inhibition of the PI3K-AKT-mTOR pathway in breast cancer
cells. Biomed Pharmacother. 77:37–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bourguignon LY, Spevak CC, Wong G, Xia W
and Gilad E: Hyaluronan-CD44 interaction with protein kinase
C(epsilon) promotes oncogenic signaling by the stem cell marker
Nanog and the Production of microRNA-21, leading to down-regulation
of the tumor suppressor protein PDCD4, anti-apoptosis, and
chemotherapy resistance in breast tumor cells. J Biol Chem.
284:26533–26546. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen
J, Su F, Yao H and Song E: Up-regulation of miR-21 mediates
resistance to trastuzumab therapy for breast cancer. J Biol Chem.
286:19127–19137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Müller V, Gade S, Steinbach B, Loibl S,
von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching
PA, et al: Changes in serum levels of miR-21, miR-210, and miR-373
in HER2-positive breast cancer patients undergoing neoadjuvant
therapy: A translational research project within the Geparquinto
trial. Breast Cancer Res Treat. 147:61–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Deng J, Lei W, Fu JC, Zhang L, Li JH and
Xiong JP: Targeting miR-21 enhances the sensitivity of human colon
cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys
Res Commun. 443:789–795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Li B, Ren S, Li X, Wang Y, Garfield D,
Zhou S, Chen X, Su C, Chen M, Kuang P, et al: miR-21 overexpression
is associated with acquired resistance of EGFR-TKI in non-small
cell lung cancer. Lung Cancer. 83:146–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Shen H, Zhu F, Liu J, Xu T, Pei D, Wang R,
Qian Y, Li Q, Wang L, Shi Z, et al: Alteration in Mir-21/PTEN
expression modulates gefitinib resistance in non-small cell lung
cancer. PLoS One. 9:e1033052014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wang S, Su X, Bai H, Zhao J, Duan J, An T,
Zhuo M, Wang Z, Wu M, Li Z, et al: Identification of plasma
microRNA profiles for primary resistance to EGFR-TKIs in advanced
non-small cell lung cancer (NSCLC) patients with EGFR activating
mutation. J Hematol Oncol. 8:1272015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wu ZH, Tao ZH, Zhang J, Li T, Ni C, Xie J,
Zhang JF and Hu XC: miRNA-21 induces epithelial to mesenchymal
transition and gemcitabine resistance via the PTEN/AKT pathway in
breast cancer. Tumour Biol. 37:7245–7254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yu Y, Kanwar SS, Patel BB, Oh PS, Nautiyal
J, Sarkar FH and Majumdar AP: MicroRNA-21 induces stemness by
downregulating transforming growth factor beta receptor 2 (TGFβR2)
in colon cancer cells. Carcinogenesis. 33:68–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Feng YH, Wu CL, Shiau AL, Lee JC, Chang
JG, Lu PJ, Tung CL, Feng LY, Huang WT and Tsao CJ:
MicroRNA-21-mediated regulation of Sprouty2 protein expression
enhances the cytotoxic effect of 5-fluorouracil and metformin in
colon cancer cells. Int J Mol Med. 29:920–926. 2012.PubMed/NCBI
|
|
83
|
Liu ZL, Wang H, Liu J and Wang ZX:
MicroRNA-21 (miR-21) expression promotes growth, metastasis, and
chemo- or radioresistance in non-small cell lung cancer cells by
targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wei X, Wang W, Wang L, Zhang Y, Zhang X,
Chen M, Wang F, Yu J, Ma Y and Sun G: MicroRNA-21 induces
5-fluorouracil resistance in human pancreatic cancer cells by
regulating PTEN and PDCD4. Cancer Med. 5:693–702. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Paik WH, Kim HR, Park JK, Song BJ, Lee SH
and Hwang JH: Chemosensitivity induced by down-regulation of
microRNA-21 in gemcitabine-resistant pancreatic cancer cells by
indole-3-carbinol. Anticancer Res. 33:1473–1481. 2013.PubMed/NCBI
|
|
86
|
Shi GH, Ye DW, Yao XD, Zhang SL, Dai B,
Zhang HL, Shen YJ, Zhu Y, Zhu YP, Xiao WJ, et al: Involvement of
microRNA-21 in mediating chemo-resistance to docetaxel in
androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin.
31:867–873. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Tomimaru Y, Eguchi H, Nagano H, Wada H,
Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M,
Umeshita K, et al: MicroRNA-21 induces resistance to the
anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular
carcinoma cells. Br J Cancer. 103:1617–1626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
He C, Dong X, Zhai B, Jiang X, Dong D, Li
B, Jiang H, Xu S and Sun X: miR-21 mediates sorafenib resistance of
hepatocellular carcinoma cells by inhibiting autophagy via the
PTEN/Akt pathway. Oncotarget. 6:28867–28881. 2015.PubMed/NCBI
|
|
89
|
Echevarría-Vargas IM, Valiyeva F and
Vivas-Mejía PE: Upregulation of miR-21 in cisplatin resistant
ovarian cancer via JNK-1/c-Jun pathway. PLoS One. 9:e970942014.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Xie Z, Cao L and Zhang J: miR-21 modulates
paclitaxel sensitivity and hypoxia-inducible factor-1α expression
in human ovarian cancer cells. Oncol Lett. 6:795–800.
2013.PubMed/NCBI
|
|
91
|
Lan F, Pan Q, Yu H and Yue X: Sulforaphane
enhances temozolomide-induced apoptosis because of down-regulation
of miR-21 via Wnt/β-catenin signaling in glioblastoma. J Neurochem.
134:811–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Shi L, Chen J, Yang J, Pan T, Zhang S and
Wang Z: miR-21 protected human glioblastoma U87MG cells from
chemotherapeutic drug temozolomide induced apoptosis by decreasing
Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 1352:255–264.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhou X, Ren Y, Liu A, Jin R, Jiang Q,
Huang Y, Kong L, Wang X and Zhang L: WP1066 sensitizes oral
squamous cell carcinoma cells to cisplatin by targeting
STAT3/miR-21 axis. Sci Rep. 4:74612014. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Bourguignon LY, Earle C, Wong G, Spevak CC
and Krueger K: Stem cell marker (Nanog) and Stat-3 signaling
promote MicroRNA-21 expression and chemoresistance in
hyaluronan/CD44-activated head and neck squamous cell carcinoma
cells. Oncogene. 31:149–160. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Yang GD, Huang TJ, Peng LX, Yang CF, Liu
RY, Huang HB, Chu QQ, Yang HJ, Huang JL, Zhu ZY, et al:
Epstein-Barr Virus_Encoded LMP1 upregulates microRNA-21 to promote
the resistance of nasopharyngeal carcinoma cells to
cisplatin-induced Apoptosis by suppressing PDCD4 and Fas-L. PLoS
One. 8:e783552013. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Tao J, Lu Q, Wu D, Li P, Xu B, Qing W,
Wang M, Zhang Z and Zhang W: microRNA-21 modulates cell
proliferation and sensitivity to doxorubicin in bladder cancer
cells. Oncol Rep. 25:1721–1729. 2011.PubMed/NCBI
|
